266 related articles for article (PubMed ID: 16849475)
1. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.
Li B; Allendorf DJ; Hansen R; Marroquin J; Ding C; Cramer DE; Yan J
J Immunol; 2006 Aug; 177(3):1661-9. PubMed ID: 16849475
[TBL] [Abstract][Full Text] [Related]
2. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
[TBL] [Abstract][Full Text] [Related]
3. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
Vetvicka V; Thornton BP; Ross GD
J Clin Invest; 1996 Jul; 98(1):50-61. PubMed ID: 8690804
[TBL] [Abstract][Full Text] [Related]
4. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
5. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.
Hong F; Yan J; Baran JT; Allendorf DJ; Hansen RD; Ostroff GR; Xing PX; Cheung NK; Ross GD
J Immunol; 2004 Jul; 173(2):797-806. PubMed ID: 15240666
[TBL] [Abstract][Full Text] [Related]
6. Cell type-specific differences in β-glucan recognition and signalling in porcine innate immune cells.
Baert K; Sonck E; Goddeeris BM; Devriendt B; Cox E
Dev Comp Immunol; 2015 Jan; 48(1):192-203. PubMed ID: 25453580
[TBL] [Abstract][Full Text] [Related]
7. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
[TBL] [Abstract][Full Text] [Related]
8. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan.
Allendorf DJ; Yan J; Ross GD; Hansen RD; Baran JT; Subbarao K; Wang L; Haribabu B
J Immunol; 2005 Jun; 174(11):7050-6. PubMed ID: 15905548
[TBL] [Abstract][Full Text] [Related]
9. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity.
Gelderman KA; Lam S; Sier CF; Gorter A
Eur J Immunol; 2006 Apr; 36(4):977-84. PubMed ID: 16525993
[TBL] [Abstract][Full Text] [Related]
10. Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18).
Roubey RA; Ross GD; Merrill JT; Walton F; Reed W; Winchester RJ; Buyon JP
J Immunol; 1991 May; 146(10):3557-62. PubMed ID: 1673986
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system.
Okazawa H; Motegi S; Ohyama N; Ohnishi H; Tomizawa T; Kaneko Y; Oldenborg PA; Ishikawa O; Matozaki T
J Immunol; 2005 Feb; 174(4):2004-11. PubMed ID: 15699129
[TBL] [Abstract][Full Text] [Related]
12. Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury.
Cramer DE; Allendorf DJ; Baran JT; Hansen R; Marroquin J; Li B; Ratajczak J; Ratajczak MZ; Yan J
Blood; 2006 Jan; 107(2):835-40. PubMed ID: 16179370
[TBL] [Abstract][Full Text] [Related]
13. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan.
Yan J; Vetvicka V; Xia Y; Hanikýrová M; Mayadas TN; Ross GD
Immunopharmacology; 2000 Jan; 46(1):39-54. PubMed ID: 10665778
[TBL] [Abstract][Full Text] [Related]
14. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.
Vĕtvicka V; Hanikýrová M; Vĕtvicková J; Ross GD
Clin Exp Immunol; 1999 Feb; 115(2):229-35. PubMed ID: 9933447
[TBL] [Abstract][Full Text] [Related]
15. Activation of CR3-mediated phagocytosis by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol 3-kinase, and protein kinase C zeta.
Lutz MA; Correll PH
J Leukoc Biol; 2003 Jun; 73(6):802-14. PubMed ID: 12773513
[TBL] [Abstract][Full Text] [Related]
16. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways.
Li B; Cramer D; Wagner S; Hansen R; King C; Kakar S; Ding C; Yan J
Clin Immunol; 2007 Aug; 124(2):170-81. PubMed ID: 17572156
[TBL] [Abstract][Full Text] [Related]
17. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.
Yan J; Allendorf DJ; Brandley B
Expert Opin Biol Ther; 2005 May; 5(5):691-702. PubMed ID: 15934844
[TBL] [Abstract][Full Text] [Related]
18. Role of complement receptor type three and serum opsonins in the neutrophil response to yeast.
Cain JA; Newman SL; Ross GD
Complement; 1987; 4(2):75-86. PubMed ID: 3040333
[TBL] [Abstract][Full Text] [Related]
19. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy.
Liu J; Gunn L; Hansen R; Yan J
Exp Mol Pathol; 2009 Jun; 86(3):208-14. PubMed ID: 19454271
[TBL] [Abstract][Full Text] [Related]
20. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models.
Salvador C; Li B; Hansen R; Cramer DE; Kong M; Yan J
Clin Cancer Res; 2008 Feb; 14(4):1239-47. PubMed ID: 18281559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
